{"cluster": 16, "subcluster": 19, "abstract_summ": "Therefore, targeting the unbalanced RAS and ACE2 down-regulation with vitamin D in SARS-CoV-2 infection is a potential therapeutic approach to combat COVID-19 and induced ARDS.Angiotensin-converting enzyme 2 (ACE 2) is the entry receptor for the novel coronavirus SARS-CoV-2, the aetiological agent of COVID-19.Comparison with lavage samples from controls identify a critical imbalance in RAS represented by decreased expression of ACE in combination with increases in ACE2, renin (REN) , angiotensin (AGT), key RAS receptors (AGTR2, AGTR1), kinogen (KNG) and the kallikrein enzymes (KLKB1, many of KLK-1-15) that activate it, and both bradykinin receptors (BDKRB1, BDKRB2).Given that angiotensin receptor blockers (ARBs) and an ACE inhibitor (ACEI) upregulated ACE2 expression in animal studies, the concern might arise regarding whether ARBs and ACEIs would increase the morbidity and mortality of COVID-19.Angiotensin-converting enzyme 2 (ACE2), a part of the renin-angiotensin system (RAS), serves as the major entry point into cells for SARS-CoV-2 which attaches to human ACE2, thereby reducing the expression of ACE2 and causing lung injury and pneumonia.In addition to the direct viral effects and inflammatory and immune factors associated with COVID-19 pathogenesis, ACE2 downregulation and the imbalance between the RAS and ACE2/angiotensin-(1\u20137)/MAS after infection may also contribute to multiple organ injury in COVID-19.", "title_summ": "Modeling the molecular impact of the SARS-CoV-2 infection on the renin-angiotensin systemAngiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infectionInteractions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors\u2014lessons from available evidence and insights into COVID-19Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolismRole of angiotensin-converting enzyme 2 (ACE2) in COVID-19A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.", "title_abstract_phrases": "Therefore, targeting the unbalanced RAS and ACE2 down-regulation with vitamin D in SARS-CoV-2 infection is a potential therapeutic approach to combat COVID-19 and induced ARDS.The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?Angiotensin-converting enzyme 2 (ACE 2) is the entry receptor for the novel coronavirus SARS-CoV-2, the aetiological agent of COVID-19.Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors\u2014lessons from available evidence and insights into COVID-19The rapid spread of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to an ongoing pandemic of coronavirus disease 2019 (COVID-19).Comparison with lavage samples from controls identify a critical imbalance in RAS represented by decreased expression of ACE in combination with increases in ACE2, renin (REN) , angiotensin (AGT), key RAS receptors (AGTR2, AGTR1), kinogen (KNG) and the kallikrein enzymes (KLKB1, many of KLK-1-15) that activate it, and both bradykinin receptors (BDKRB1, BDKRB2).Given that angiotensin receptor blockers (ARBs) and an ACE inhibitor (ACEI) upregulated ACE2 expression in animal studies, the concern might arise regarding whether ARBs and ACEIs would increase the morbidity and mortality of COVID-19.These bradykinin-driven outcomes explain many of the symptoms being observed in COVID-19.Modeling the molecular impact of the SARS-CoV-2 infection on the renin-angiotensin systemInfection by the SARS-CoV-2 virus is mediated by the binding of its spike protein to the membrane-bound angiotensin converting enzyme 2 (ACE2), which plays a pivotal role in the renin-angiotensin system (RAS)."}